Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 5.61Panacea Biotec Ltd, operating within the Healthcare Services sector, presents a mixed financial picture. The company demonstrates strong solvency and growth, indicating a solid long-term financial foundation and significant expansion in key areas such as revenue, operating profit, and earnings per share. However, its liquidity position is concerning, suggesting potential difficulties in meeting short-term obligations. Efficiency ratios also raise concerns, indicating challenges in effectively utilizing assets. Profitability metrics are varied, with some areas showing strength while others reveal weaknesses. Overall, while Panacea Biotec exhibits robust growth and solvency, improvements in liquidity, efficiency, and consistent profitability are essential for sustained financial health. The company's future will depend on its ability to address these challenges and capitalize on its growth potential.
Health Score : 5.61Panacea Biotec Ltd, operating within the Healthcare Services sector, presents a mixed financial picture. The company demonstrates strong solvency and growth, indicating a solid long-term financial foundation and significant expansion in key areas such as revenue, operating profit, and earnings per share. However, its liquidity position is concerning, suggesting potential difficulties in meeting short-term obligations. Efficiency ratios also raise concerns, indicating challenges in effectively utilizing assets. Profitability metrics are varied, with some areas showing strength while others reveal weaknesses. Overall, while Panacea Biotec exhibits robust growth and solvency, improvements in liquidity, efficiency, and consistent profitability are essential for sustained financial health. The company's future will depend on its ability to address these challenges and capitalize on its growth potential.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
-80.10
Industry Median
7.70
Small Cap Median
7.70
P/E RATIO
-444.20
P/B RATIO
2.87
Industry Median
1.53
Small Cap Median
1.53
P/S RATIO
3.86
Industry Median
3.62
Small Cap Median
3.62
Others
PEG RATIO
0.00
EV/EBITDA RATIO
75.95
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹390.9 as on Sep 1, 2026.
Growth Score : 10.00Panacea Biotec demonstrates strong growth across key metrics. The revenue growth rate, operating profit growth rate, earnings per share growth, asset growth rate and net income growth rate show high. This suggests the company is effectively expanding its operations and increasing its profitability. High growth score can attract investors and support future development.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 5.76 | -30.41 | 21.52 | 0 | 14.49 |
| Operating Profit Growth Rate | -116.88 | -653.85 | 79.59 | -25 | 80 |
| Earnings Per Share (EPS) Growth | 830.22 | -103.08 | 96.49 | -621.05 | 35.77 |
| Asset Growth Rate | 49.32 | -27.74 | -2.36 | 3.95 | -2.17 |
| Net Income Growth Rate | 828.38 | -103.15 | 94.12 | -350 | 22.22 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Advanced Enzyme Technologies Ltd | 7.86 | 19.60 | Highly Overvalued | 229.00 | 11.77 | 174.00 |
| 2 | Panacea Biotec Ltd | 5.61 | -444.20 | Neutral | -5.00 | -4.88 | -7.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Panacea Biotec Ltd. is an Indian pharmaceutical company primarily engaged in research, development, manufacturing, and marketing of pharmaceutical formulations, biopharmaceuticals, and vaccines. It focuses on therapeutic areas like oncology, diabetes, pain management, and gastroenterology, serving both domestic and international markets with a strong emphasis on R&D.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Panacea Biotec Ltd's P/E ratio (TTM) is -80.10, compared to the industry median of 7.70 and large cap median of 7.70.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Panacea Biotec Ltd's P/B ratio is 2.87, compared to the industry median of 1.53 and large cap median of 1.53.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Panacea Biotec Ltd's P/S ratio is 3.86, compared to the industry median of 3.62 and large cap median of 3.62.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Panacea Biotec Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Panacea Biotec Ltd's EV/EBITDA ratio is 75.95.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Panacea Biotec Ltd's ROE is -0.84%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Panacea Biotec Ltd's ROA is -0.40%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Panacea Biotec Ltd's ROCE is -2%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Panacea Biotec Ltd's operating margin is -0.78%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Panacea Biotec Ltd's net margin is -1.09%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Panacea Biotec Ltd's current ratio is 1.32.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Panacea Biotec Ltd's debt-to-equity ratio is 0.03.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Panacea Biotec Ltd's interest coverage ratio is -0.17.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Panacea Biotec Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Panacea Biotec Ltd's EPS is 35.77.
(Source line: "Ratios as of 11 Oct 2026, based on last traded price of ₹390.90. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1984
Headquarters: New Delhi, Delhi
Core Offerings: Vaccines, Oncology products, Diabetes management products, Gastroenterology products, Pain management products
Stock Listing: NSE (PANACEABIO), BSE (531349)
Promoter: Dr. S. K. Chaudhary & Associates
Panacea Biotec Ltd. was incorporated in 1984. The company commenced pharmaceutical formulations manufacturing in 1991 and ventured into biopharmaceutical research by 1995. A significant milestone was achieved in 1996 with the launch of India's first fully liquid combination vaccine. The company was listed on Indian stock exchanges (NSE & BSE) in 2005. In 2008, Panacea Biotec expanded its portfolio by launching oncology products, steadily growing its presence in both domestic and international pharmaceutical and vaccine markets.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceuticals (incl. Vaccines & Biopharma) | 100% | Company-wide EBITDA margin ~10-12% (based on recent TTM data) |
Pharmaceutical Formulations: Focuses on manufacturing and marketing a comprehensive range of pharmaceutical formulations spanning therapeutic areas such as oncology, diabetes, gastroenterology, pain management, and nutritionals. Products cater to diverse patient needs across chronic and acute conditions.
Vaccines: Engaged in the research, development, and manufacturing of various human vaccines, including advanced combination vaccines. The company supplies vaccines to both the Indian public health system and international markets, including UNICEF.
Biopharmaceuticals: Involved in the research, development, and eventual manufacturing of biosimilar products and other complex biopharmaceuticals, leveraging advanced biotechnology capabilities.
Dr. S. K. Chaudhary: Chairman and Managing Director. He is the founder of Panacea Biotec and possesses over four decades of extensive experience in the pharmaceutical industry, providing strategic vision and leadership to the company.
Panacea Biotec Pharma Ltd.
Panacea Biotec (Singapore) Pte. Ltd.
Panacea Biotec Germany GmbH
Panacea Biotec Europe Limited (UK)
The company completed a Rights Issue in December 2020. No major recent bonus issues or significant M&A activities on record since then.
The Panacea Biotec Ltd share price today is ₹390.90 on NSE (PANACEABIO), as of 11 Oct 2026.
As of 11 Oct 2026, Panacea Biotec Ltd share price is ₹390.90, with previous close ₹390.90. Today's range is ₹390.90 to ₹390.90. The 52-week range is ₹N/A to ₹N/A.
As of today, Panacea Biotec Ltd's market cap is ₹2,470.49 crore (Small Cap).
Panacea Biotec Ltd's current P/E ratio is -80.10, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 31.
Panacea Biotec Ltd's current P/B ratio is 2.87.
Panacea Biotec Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Panacea Biotec Ltd's EPS (TTM) is ₹35.77.
Panacea Biotec Ltd. is an Indian pharmaceutical company primarily engaged in research, development, manufacturing, and marketing of pharmaceutical formulations, biopharmaceuticals, and vaccines. It focuses on therapeutic areas like oncology, diabetes, pain management, and gastroenterology, serving both domestic and international markets with a strong emphasis on R&D.
Panacea Biotec Ltd is promoted by Dr. S. K. Chaudhary & Associates, holding 72.48% as of 11 Oct 2026.
Panacea Biotec Ltd is listed on NSE (PANACEABIO) and BSE (531349). Its next quarterly results are expected on August 2024 (Q1 FY25).
Cash Earnings Per Share (Cash EPS)